SecBot SecBot
6-K ·Filed Jun 23, 2026

DRTS

Alpha Tau Medical Ltd.
BULLISH
Impact 6/10
Horizonweeks Processed4mo ago SEC0001213900-26-071076
Notable filing: 6-K
Actionable Insight ▲ Bullish

This is a positive clinical proof-of-concept for Alpha DaRT in glioblastoma outside the U.S., but it is a single-patient case under a broad-access protocol, not a controlled trial. Traders should watch for enrollment updates and data from the U.S. REGAIN trial, as well as any subsequent regulatory or partnership developments that could de-risk the program.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.05
T+0 close · Jun 23, 2026 · via day close
Latest settled
+54.13%
T+60 · $15.49
Vs SPY
+51.29%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 24 $10.05entry
  2. T+1 · 5mo ago +11.14%α +11.00% · $11.17
  3. T+5 · 5mo ago +25.77%α +24.06% · $12.64
  4. T+20 · 4mo ago +29.45%α +27.52% · $13.01
  5. T+60 · 2mo ago +54.13%α +51.29% · $15.49
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau announced the first-ever treatment of a recurrent glioblastoma patient outside the U.S. using its Alpha DaRT technology at Hadassah University Medical Center in Israel. The procedure was completed safely without unexpected complications, marking the first international clinical application of the brain-specific delivery system and adding momentum to the ongoing U.S. REGAIN trial.

Key Facts

  • First recurrent glioblastoma patient treated with Alpha DaRT outside the U.S., and first in Israel, at Hadassah University Medical Center.
  • Procedure used proprietary brain applicator with real-time stereotactic neuro-navigation via a single minimally-invasive burr hole.
  • Patient was a 77-year-old male with recurrent glioblastoma following surgery and radiation therapy; procedure completed safely without unexpected complications.
  • Treatment was under the ALL clinical protocol, a broad-access study at Hadassah open to patients with solid tumors amenable to Alpha DaRT.
  • The company references its multicenter U.S. Recurrent GBM REGAIN trial, which is continuing recruitment following interim results and FDA clearance to proceed to full enrollment with two new U.S. academic centers.

Financial Impact

No financial figures provided; clinical milestone with no revenue or cost data disclosed.

Risk Factors

  • Single-patient case under a broad-access protocol; no controlled efficacy data provided.
  • Glioblastoma is a highly aggressive disease; safety and efficacy in larger populations remain unproven.
  • Company is pre-revenue and will require additional capital to fund ongoing trials and operations.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-071076
Document: ea029546701ex99-1.htm0001213900-26-071076
Document: 0001213900-26-071076-index-headers.html0001213900-26-071076
Document: 0001213900-26-071076-index.html0001213900-26-071076
Document: 0001213900-26-071076.txt0001213900-26-071076

US Market Status

Market Closed · Opens in 8h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 23, 2026